Expression of sialidase and dystroglycan in human glomerular diseases | Zendy

Nils P. J. Vogtländer | Zendy; Johan van der Vlag | Zendy; Marinka A.H. Bakker | Zendy; H. B. P. M. Dijkman | Zendy; Ron A. Wevers | Zendy; Kevin P. Campbell | Zendy; J F M Wetzels | Zendy; Jo H. M. Berden | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Expression of sialidase and dystroglycan in human glomerular diseases

Author(s) -

Nils P. J. Vogtländer,

Johan van der Vlag,

Marinka A.H. Bakker,

H. B. P. M. Dijkman,

Ron A. Wevers,

Kevin P. Campbell,

J F M Wetzels,

Jo H. M. Berden

Publication year - 2009

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfp465

Subject(s) - sialidase , sialic acid , medicine , focal segmental glomerulosclerosis , endocrinology , podocyte , dystroglycan , proteinuria , laminin , pathology , kidney , biology , biochemistry , immunology , neuraminidase , extracellular matrix , virus

alpha-Dystroglycan (alpha-DG) is a negatively charged glycoprotein that covers the surface of podocytes. A decreased glomerular expression of alpha-DG has been described in minimal change nephropathy (MCN), but not in focal segmental glomerulosclerosis (FSGS). This was suggested as a tool to distinguish these diseases. Sialic acid is a negatively charged carbohydrate extensively present on both alpha-DG and podocalyxin, which is also expressed on podocytes. Intrarenal perfusion with bacterial sialidase leads to foot process effacement and proteinuria. This is the first study on the expression of endogenous glomerular sialidase; furthermore, the expression of dystroglycan was re-evaluated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research